Real-world safety of aliskiren in primary hypertension: A cross-database study
Fig 6
Cumulative incidence of adverse events related to aliskiren, highlighting the early risk period.
Distribution of time to adverse event onset (days) for the aliskiren, with a median time to event of 62.00 days and an interquartile range (IQR) of 7.00-282.00 days.